Watch Ticker

Cartesian Therapeutics, Inc. Common Stock

Go to Cartesian Therapeutics, Inc. Common Stock Website

$12.26

-0.07 (-0.57%)

Live

Previous Close

$12.33

Day Range

$12.02 - $12.43

Previous Day Range

$12.06 - $13.1

Market Cap

$320.0 million USD

Day Vol.

15653

Previous Day Vol.

77855

Currency

USD

Primary Exchange

None

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages ...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Vandana Singh - AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

AstraZeneca reported positive Phase 3 trial results for gefurulimab, a drug candidate treating generalized myasthenia gravis, demonstrating significant improvement in patient symptoms with no new safety concerns.

Related tickers: AZN, JNJ, AMGN, RNAC.

Read Full Article

N/A - Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Cartesian Therapeutics reported positive long-term results from its Phase 2b trial of Descartes-08 in myasthenia gravis, with plans to initiate a Phase 3 trial in Q2 2025. The company also expects to report preliminary data from a Phase 2 trial of Descartes-08 in systemic lupus erythematosus and initiate a Phase 2 pediatric basket trial in H2 2025. Cartesian had $182.1 million in cash as of March 31, 2025, expected to support operations into mid-2027.

Related tickers: RNAC.

Read Full Article

Trending Tickers

Please sign in to view